Esophagus CancerPROFUGONCT05390684
Predictive Model to Early Diagnosis of Anastomotic Leak After Esophagectomy and Gastrectomy.
An observational study of Esophagus Cancer and Gastric Cancer, run by Hospital Universitario La Fe at 1 site in Spain.
Trial summary
The PROFUGO study (PRedictive Model for the early diagnosis of anastomotic leak after esophagectomy and gastrectomy) is proposed as a prospective and multicenter study at spanish national level that aims to develop, with the help of artificial intelligence methods, a tool and predictive model that allows identifying… Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Esophagus Cancer, Gastric Cancer, Leak, Anastomotic
- What is being tested?
- audit of complications, prospective data collection
- How many people
- 800 participants
- Where
- 1 siteSpain
- Study dates
- 1 May 2022to 31 Dec 2023
- How long will I take part?
- 90 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with neoplasia of the esophagus or stomach with an indication for oncological surgery with curative intention in any of the centers participating in the study.
Who may be able to join
- Patients with a surgical indication and curative intent due to esophagogastric neoplasia who do not meet exclusion criteria and recruited by hospitals nationwide that decide to participate in the study will be included.
Who cannot join
- Patients under 18 or over 85 years
- Patients with chronic infections
- Patients with synchronous tumors in other locations
- Patients with autoimmune disease
- Patients who die in the operating room
- Patients who do not sign the informed consent to participate in the study
Show all 10Show fewer
- Patients in clinical stage IVB
- Surgical resection R2 (there are macroscopic remains of the tumor in the surgical field after performing the resection of the surgical piece)
- Combined intraoperative resection of other organs
- Surgeries without anastomosis
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Predictive Model to Early Diagnosis of Anastomotic Leak After Esophagectomy and Gastrectomy. PROFUGO Study.
The PROFUGO study (PRedictive Model for the early diagnosis of anastomotic leak after esophagectomy and gastrectomy) is proposed as a prospective and multicenter study at spanish national level that aims to develop, with the help of artificial intelligence methods, a tool and predictive model that allows identifying cases with a high risk of anastomotic leak (AF) and/or major complications through the analysis of different clinical and analytical variables collected during the perioperative period of patients undergoing esophagectomy or gastrectomy.
2.-HYPOTHESIS
Read more
Early identification of patients at high risk of developing AF and/or major complications after esophagogastric surgery can be carried out through the perioperative study of objective clinical variables and analytical markers.
3.-OBJECTIVE
The main objective of the study is to design a predictive model based on clinical and analytical variables that allow the identification of patients with a high risk of anastomotic leak (main variable) and/or major complication during the postoperative period of esophagogastric surgery.
4.-MATERIAL AND METHODS
- DESIGN: Prospective and multicenter study of 1 year duration.
- STUDY POPULATION: Patients diagnosed with neoplasia of the esophagus or stomach with an indication for oncological surgery with curative intent.
- INCLUSION CRITERIA: patients with surgical indication and curative intention due to esophagogastric neoplasm who do not meet exclusion criteria and recruited by hospitals nationwide that decide to participate in the study.
- EXCLUSION CRITERIA
- Patients under 18 or over 85 years
- Patients with chronic infections
- Patients with synchronous tumors in other locations
- Patients with autoimmune disease
- Patients who die in the operating room
- Patients who do not sign the informed consent to participate in the study
- Patients in clinical stage IVB
- Surgical resection R2 (there are macroscopic remains of the tumor in the surgical field after performing the resection of the surgical piece)
- Combined intraoperative resection of other organs
- Surgeries without anastomosis
- MONITORING: The patient will be monitored during the first 90 postoperative days. 5.-DURATION OF THE STUDY The time for the inclusion of patients in the study will be 1 year in each center from the incorporation of the first of their patients.
Read the detailed description
The methodological properties of the study are described below:
- - Type of design Prospective and multicenter study that aims to develop, with the help of artificial intelligence methods, a tool and predictive model that allows identifying cases with a high risk of anastomotic leak and/or major complications through the analysis of different clinical and analytical variables collected during the postoperative period. of patients undergoing esophagectomy or gastrectomy.
- - Study population Patients diagnosed with neoplasia of the esophagus or stomach with an indication for oncological surgery with curative intent in any of the centers participating in the study.
- - Inclusion and exclusion criteria Patients with a surgical indication and curative intent due to esophagogastric neoplasia who do not meet exclusion criteria and recruited by hospitals nationwide that decide to participate in the study will be included. The study exclusion criteria are:
- Patients under 18 or over 85 years
- Patients with chronic infections
- Patients with synchronous tumors in other locations
- Patients with autoimmune disease
- Patients who die in the operating room
- Patients who do not sign the informed consent to participate in the study
- Patients in clinical stage IVB
- Surgical resection R2 (there are macroscopic remains of the tumor in the surgical field after performing the resection of the surgical piece)
- Combined intraoperative resection of other organs
- Surgeries without anastomosis In addition, the following situations are considered criteria for abandonment or withdrawal of the patient from the study:
- Revocation of the informed consent expressed by the patient at any time during the study.
- Patient loss during study follow-up
- Incorrect data collection according to the indications provided
- - Sample size The purpose of the study is to recruit as many patients as possible from all national centers who wish to participate. For an alpha error of 5% (95% confidence) with a precision of 3% and estimating a number of patients with major complications (including AF) around 30%, the calculation of the sample size yields a total of 847 patients. However, the final sample size may be smaller depending on the proportion of complications detected and the statistical and artificial intelligence models to create the predictive model will be adapted to the event rate provided by the recruited sample.
- - Recruitment All patients who meet the inclusion and exclusion criteria will be offered preoperative participation in this study. Once the information has been understood (Annex 1) and the written informed consent (Annex 2) has been signed, each patient will be assigned a code that will be used to anonymously manage any of their information obtained during the study. Thus, the confidentiality of the data belonging to all the patients included in the study will be guaranteed at all times from the moment of recruitment.
- - Intervention The patient will undergo the indicated surgical intervention depending on whether it is an esophageal or gastric neoplasm, with curative intent with or without prior neoadjuvant treatment. Surgical intervention and postoperative care will be carried out in each of the centers of the national territory that commit to participate according to their usual clinical practice. Thus, the perioperative management and care protocol will be that of each center without the need to apply exceptional measures (beyond the control of the clinical and analytical variables of this study) or a homogeneous protocol in all the participating centers. The analysis and control of the preoperative clinical variables must be carried out the day before or the same day of the surgical intervention prior to it.
- - Follow up The patient will be monitored during the first 90 postoperative days, compiling all the specific variables of this study and the possible complications and mortality that occurred in this period. During the immediate postoperative period, apart from the care applied routinely in each center, patients should be evaluated daily and the clinical and laboratory variables specified later should be collected on days 1, 2, 3, 4 and 6 postoperatively. In the same way, in this postoperative course, the possible complications that appeared during the hospital stay will be compiled. Subsequently, if the patient is discharged from the hospital, a follow-up will be carried out in the outpatient consultations at 30 and 90 days to evaluate the possible complications that appear in this period and other variables studied will be completed.
- - Database and study variables
The variables collected throughout the study protocol will be collected on the following dates of assistance, care, control and follow-up of the patient.
- Conditions
- Esophagus Cancer, Gastric Cancer, Leak, Anastomotic, Complication
- Being tested
- audit of complications, prospective data collection
- Keywords
- esophagectomy, gastrectomy, leak
- Medical subject headings
- Esophageal Neoplasms, Stomach Neoplasms, Anastomotic Leak
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
audit of complications, prospective data collectionOther
Prospective colecction of data will be performed to create a predictive model of leak and major complication
What is being measured
The primary outcome is the main question the study is designed to answer.
anastomotic leak
a categorical variable divided into the following categories, according to the consensus definitions of the Consensus Group on Complications of Esophagectomy (ECCG) (27), which in this study will be applicable both to fistulas occurred after esophagectomy and after gastrectomy:
- NO: If this complication did not occur.
- I: Defect that does not require specific treatment or that can be treated medically or with diet modification
- II: Defect that requires some intervention, but not surgical, such as: drainage by interventional radiology, prosthesis placement, opening of the wound at the bedside, compression or wound healing.
- III: Defect requiring surgical intervention
Measured: 90 postoperative days
Secondary outcomes (5)
major complication
Clavien Dindo > III
Measured: 90 postoperative days
chylothorax
Categorical variable divided into the categories according to the consensus definitions of the Consensus Group on Complications of Esophagectomy (ECCG)
Measured: 90 postoperative days
plasty necrosis
Categorical variable divided into the categories according to the consensus definitions of the Consensus Group on Complications of Esophagectomy (ECCG)
Measured: 90 postoperative days
recurrent nerve plasy
Categorical variable divided into the categories according to the consensus definitions of the Esophagectomy Complications Consensus Group (ECCG)
Measured: 90 postoperative days
infection
Dichotomous variable: YES/NO.
Measured: 90 postoperative days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2022
- Study start1 May 2022
- Primary completion1 Dec 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Esophagus CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 800 participants (estimated)
- Target duration
- 90 Days
Sponsor and investigators
- Lead sponsor
- Hospital Universitario La Fe
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marcos Bruna, Hospital Universitario La Fe
- Investigators
- Marcos Bruna, Principal investigator, Hospital Universitario La Fe
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05390684
- Sponsor's protocol ID
- AEC-PROFUGO
- Acronym
- PROFUGO
- Status last verified
- May 2022
- First submitted
- 16 May 2022
- Last updated
- 25 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictive Model to Early Diagnosis of Anastomotic Leak After Esophagectomy and Gastrectomy. PROFUGO Study.
- ClinicalTrials.gov ID
- NCT05390684
- Acronym / sponsor ID
- PROFUGO / AEC-PROFUGO
- Conditions
- Esophagus Cancer, Gastric Cancer, Leak, Anastomotic, Complication
- Keywords
- esophagectomy, gastrectomy, leak
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 800 participants (estimated)
- Lead sponsor
- Hospital Universitario La FeUniversity, hospital or other
- Study start
- 1 May 2022 (actual)
- Primary completion
- 1 Dec 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 25 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The PROFUGO study (PRedictive Model for the early diagnosis of anastomotic leak after esophagectomy and gastrectomy) is proposed as a prospective and multicenter study at spanish national level that aims to develop, with the help of artificial intelligence methods, a tool and predictive model that allows identifying cases with a high risk of anastomotic leak (AF) and/or major complications through the analysis of different clinical and analytical variables collected during the perioperative period of patients undergoing esophagectomy or gastrectomy.
2.-HYPOTHESIS
Early identification of patients at high risk of developing AF and/or major complications after esophagogastric surgery can be carried out through the perioperative study of objective clinical variables and analytical markers.
3.-OBJECTIVE
The main objective of the study is to design a predictive model based on clinical and analytical variables that allow the identification of patients with a high risk of anastomotic leak (main variable) and/or major complication during the postoperative period of esophagogastric surgery.
4.-MATERIAL AND METHODS
- DESIGN: Prospective and multicenter study of 1 year duration.
- STUDY POPULATION: Patients diagnosed with neoplasia of the esophagus or stomach with an indication for oncological surgery with curative intent.
- INCLUSION CRITERIA: patients with surgical indication and curative intention due to esophagogastric neoplasm who do not meet exclusion criteria and recruited by hospitals nationwide that decide to participate in the study.
- EXCLUSION CRITERIA
- Patients under 18 or over 85 years
- Patients with chronic infections
- Patients with synchronous tumors in other locations
- Patients with autoimmune disease
- Patients who die in the operating room
- Patients who do not sign the informed consent to participate in the study
- Patients in clinical stage IVB
- Surgical resection R2 (there are macroscopic remains of the tumor in the surgical field after performing the resection of the surgical piece)
- Combined intraoperative resection of other organs
- Surgeries without anastomosis
- MONITORING: The patient will be monitored during the first 90 postoperative days. 5.-DURATION OF THE STUDY The time for the inclusion of patients in the study will be 1 year in each center from the incorporation of the first of their patients.
Detailed description
The methodological properties of the study are described below:
- - Type of design Prospective and multicenter study that aims to develop, with the help of artificial intelligence methods, a tool and predictive model that allows identifying cases with a high risk of anastomotic leak and/or major complications through the analysis of different clinical and analytical variables collected during the postoperative period. of patients undergoing esophagectomy or gastrectomy.
- - Study population Patients diagnosed with neoplasia of the esophagus or stomach with an indication for oncological surgery with curative intent in any of the centers participating in the study.
- - Inclusion and exclusion criteria Patients with a surgical indication and curative intent due to esophagogastric neoplasia who do not meet exclusion criteria and recruited by hospitals nationwide that decide to participate in the study will be included. The study exclusion criteria are:
- Patients under 18 or over 85 years
- Patients with chronic infections
- Patients with synchronous tumors in other locations
- Patients with autoimmune disease
- Patients who die in the operating room
- Patients who do not sign the informed consent to participate in the study
- Patients in clinical stage IVB
- Surgical resection R2 (there are macroscopic remains of the tumor in the surgical field after performing the resection of the surgical piece)
- Combined intraoperative resection of other organs
- Surgeries without anastomosis In addition, the following situations are considered criteria for abandonment or withdrawal of the patient from the study:
- Revocation of the informed consent expressed by the patient at any time during the study.
- Patient loss during study follow-up
- Incorrect data collection according to the indications provided
- - Sample size The purpose of the study is to recruit as many patients as possible from all national centers who wish to participate. For an alpha error of 5% (95% confidence) with a precision of 3% and estimating a number of patients with major complications (including AF) around 30%, the calculation of the sample size yields a total of 847 patients. However, the final sample size may be smaller depending on the proportion of complications detected and the statistical and artificial intelligence models to create the predictive model will be adapted to the event rate provided by the recruited sample.
- - Recruitment All patients who meet the inclusion and exclusion criteria will be offered preoperative participation in this study. Once the information has been understood (Annex 1) and the written informed consent (Annex 2) has been signed, each patient will be assigned a code that will be used to anonymously manage any of their information obtained during the study. Thus, the confidentiality of the data belonging to all the patients included in the study will be guaranteed at all times from the moment of recruitment.
- - Intervention The patient will undergo the indicated surgical intervention depending on whether it is an esophageal or gastric neoplasm, with curative intent with or without prior neoadjuvant treatment. Surgical intervention and postoperative care will be carried out in each of the centers of the national territory that commit to participate according to their usual clinical practice. Thus, the perioperative management and care protocol will be that of each center without the need to apply exceptional measures (beyond the control of the clinical and analytical variables of this study) or a homogeneous protocol in all the participating centers. The analysis and control of the preoperative clinical variables must be carried out the day before or the same day of the surgical intervention prior to it.
- - Follow up The patient will be monitored during the first 90 postoperative days, compiling all the specific variables of this study and the possible complications and mortality that occurred in this period. During the immediate postoperative period, apart from the care applied routinely in each center, patients should be evaluated daily and the clinical and laboratory variables specified later should be collected on days 1, 2, 3, 4 and 6 postoperatively. In the same way, in this postoperative course, the possible complications that appeared during the hospital stay will be compiled. Subsequently, if the patient is discharged from the hospital, a follow-up will be carried out in the outpatient consultations at 30 and 90 days to evaluate the possible complications that appear in this period and other variables studied will be completed.
- - Database and study variables
The variables collected throughout the study protocol will be collected on the following dates of assistance, care, control and follow-up of the patient.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 90 Days
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with neoplasia of the esophagus or stomach with an indication for oncological surgery with curative intention in any of the centers participating in the study.
Key inclusion criteria (1 listed)
- Patients with a surgical indication and curative intent due to esophagogastric neoplasia who do not meet exclusion criteria and recruited by hospitals nationwide that decide to participate in the study will be included.
Key exclusion criteria (10 listed)
- Patients under 18 or over 85 years
- Patients with chronic infections
- Patients with synchronous tumors in other locations
- Patients with autoimmune disease
- Patients who die in the operating room
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| audit of complications, prospective data collectionProspective colecction of data will be performed to create a predictive model of leak and major complication | Other | – |
Primary outcome
anastomotic leak
Time frame: 90 postoperative days
a categorical variable divided into the following categories, according to the consensus definitions of the Consensus Group on Complications of Esophagectomy (ECCG) (27), which in this study will be applicable both to fistulas occurred after esophagectomy and after gastrectomy: * NO: If this complication did not occur. * I: Defect that does not require specific treatment or that can be treated medically or with diet modification * II: Defect that requires some intervention, but not surgical, such as: drainage by interventional radiology, prosthesis placement, opening of the wound at the bedside, compression or wound healing. * III: Defect requiring surgical intervention
5 secondary outcomes
major complication
Time frame: 90 postoperative days
chylothorax
Time frame: 90 postoperative days
plasty necrosis
Time frame: 90 postoperative days
recurrent nerve plasy
Time frame: 90 postoperative days
infection
Time frame: 90 postoperative days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 May 2022.
- Individual participant dataSharing planned: No
Related trials for Esophagus Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingObservational study
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
RecruitingPhase 4
Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)
Barrett Esophagus
RecruitingPhase 1/2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marcos Bruna principal investigator
Hospital Universitario La Fe
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Esophagus Cancer and Gastric Cancer, run by Hospital Universitario La Fe at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
anastomotic leak (time frame: 90 postoperative days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2022.